Choroidal Neovascularization Market 2024-2032: Size, Share, Trends, Analysis and Research Report
The latest report by IMARC Group, titled “Choroidal Neovascularization Market Report by Product Type (Intravenous, Intravitreal), Diagnosis (Fluorescein Angiography (FA), Indocyanine Green (ICG) Angiography, Spectral Domain Optical Coherence Tomography (OCT), and Others), Treatment Type (Angiogenesis Inhibitors Injection, Photodynamic Therapy, Laser photocoagulation, Low-dose Radiation Therapy, Surgery), Application (Extreme Myopia, Malignant Myopic Degeneration, Age-Related Developments), and Region 2024-2032“, The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.
Choroidal neovascularization (CNV) is a condition where abnormal new blood vessels grow in the of the eye under the retina. This health issue is a significant concern in eye care as it can lead to severe vision loss, often linked to age-related macular degeneration (AMD). CN when these irregular blood vessels break through the Bruch's membrane, a fragile barrier separating the choroid from the retina, causing fluid or blood to leak into the mac the central part of the retina responsible for The build-up of fluid and blood disrupts normal macular function, resulting in distorted or blurred vision. CNV can manifest in different types, such as classic CNV, occult CNV, and minimally classic CNV.
Choroidal Neovascularization Market Trends and Drivers:
The global driven by the increasing, which is leading to a higher incidence of age-related macular degeneration and associated conditions like CNV. As a result, there is a growing demand for accurate diagnostic tools and effective treatment options, which is expected to intensify as the global population continues to age. Advances in diagnostic technologies, such as OCT and FA imaging, are improving the detection and diagnosis of CNV, enabling timely interventions like anti-VEGF therapies. Companies that specialize in innovative diagnostic solutions and imaging equipment are well-positioned to capitalize on this trend. The shift towards personalized medicine is also influencing the CNV market, with treatment strategies being tailored to individual patient characteristics, such as genetic profiles and biomarkers, to optimize outcomes and minimize side effects. Furthermore, to effective CNV treatments, implementing initiatives to simplify therapy approval processes and enhance reimbursement systems.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/choroidal-neovascularization-market/requestsample
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Product Type:
- Intravenous
- Intravitreal
Breakup by Type of Diagnosis:
- Fluorescein Angiography (FA)
- Indocyanine Green (ICG) Angiography
- Spectral Domain Optical Coherence Tomography (OCT)
- Others
Breakup by Treatment Type:
- Angiogenesis Inhibitors Injection
- Photodynamic Therapy
- Laser photocoagulation
- Low-dose Radiation Therapy
- Surgery
Breakup by Application:
- Extreme Myopia
- Malignant Myopic Degeneration
- Age-Related Developments
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences Inc.
- F. Hoffmann-La Roche AG
- MaaT Pharma, Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
Post a Comment